These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31377206)

  • 1. Improved Outcome of a Pediatric-Inspired Protocol for High-Risk Adolescent and Young Adult Acute Lymphoblastic Leukemia Patients Using Peg-Asparaginase and Escalating Dose of Methotrexate: Tolerability and Outcome.
    Hanbali A; Kotb A; El Fakih R; Alfraih F; Ahmed SO; Shaheen M; Hashmi S; Alhayli S; Alahmari A; Riash MA; Rasheed W; Alzahrani H; Alsharif F; Chaudhri N; Almohareb F; Aljurf M
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):670-677. PubMed ID: 31377206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
    Testi AM; Canichella M; Vitale A; Piciocchi A; Guarini A; Starza ID; Cavalli M; De Propris MS; Messina M; Elia L; Moleti ML; Martino B; Luppi M; D'Aloisio M; Candoni A; Conter V; Fazi P; Vignetti M; Chiaretti S; Foà R
    Am J Hematol; 2021 Mar; 96(3):292-301. PubMed ID: 33284999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
    Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
    J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Geyer MB; Ritchie EK; Rao AV; Vemuri S; Flynn J; Hsu M; Devlin SM; Roshal M; Gao Q; Shukla M; Salcedo JM; Maslak P; Tallman MS; Douer D; Park JH
    Haematologica; 2021 Aug; 106(8):2086-2094. PubMed ID: 33054114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
    Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
    Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
    Dunsmore KP; Winter SS; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Rabin KR; Zweidler-Mckay PA; Raetz EA; Loh ML; Schultz KR; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2020 Oct; 38(28):3282-3293. PubMed ID: 32813610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase.
    Perusini MA; Andrews C; Atenafu EG; Gupta V; Maze D; Schuh AC; Yee KW; Bankar A; Davidson MB; Richard-Carpentier G; Chan SM; Sibai J; Schimmer AD; Minden MD; Sibai H
    Hematology; 2024 Dec; 29(1):2329027. PubMed ID: 38526239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.
    DeAngelo DJ; Stevenson KE; Dahlberg SE; Silverman LB; Couban S; Supko JG; Amrein PC; Ballen KK; Seftel MD; Turner AR; Leber B; Howson-Jan K; Kelly K; Cohen S; Matthews JH; Savoie L; Wadleigh M; Sirulnik LA; Galinsky I; Neuberg DS; Sallan SE; Stone RM
    Leukemia; 2015 Mar; 29(3):526-34. PubMed ID: 25079173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Derman BA; Streck M; Wynne J; Christ TN; Curran E; Stock W; Knoebel RW
    Leuk Lymphoma; 2020 Mar; 61(3):614-622. PubMed ID: 31680584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adolescent and young adult Philadelphia negative B cell acute lymphoblastic leukemia: results of the Chilean protocol LLA 15-30].
    Puga B; Guerra C; Molina J; Cabrera ME; Pilleux L; Calderón S; Rojas C; Vergara CG; Rojas H; Muñoz L; Lois V; Aspillaga A; Pizarro A
    Rev Med Chil; 2014 Jun; 142(6):707-15. PubMed ID: 25327315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
    Cooperation Group of Phase II Clinical Trial of PEG-Asp
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
    Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
    J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
    Hayashi RJ; Winter SS; Dunsmore KP; Devidas M; Chen Z; Wood BL; Hermiston ML; Teachey DT; Perkins SL; Miles RR; Raetz EA; Loh ML; Winick NJ; Carroll WL; Hunger SP; Lim MS; Gross TG; Bollard CM
    J Clin Oncol; 2020 Sep; 38(26):3062-3070. PubMed ID: 32552472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
    Aguayo A; Cortes J; Thomas D; Pierce S; Keating M; Kantarjian H
    Cancer; 1999 Oct; 86(7):1203-9. PubMed ID: 10506705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
    Guzauskas GF; Villa KF; Vanhove GF; Fisher VL; Veenstra DL
    J Adolesc Young Adult Oncol; 2017 Mar; 6(1):53-61. PubMed ID: 27779442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study.
    Petersdorf SH; Kopecky KJ; Head DR; Boldt DH; Balcerzak SP; Wun T; Roy V; Veith RW; Appelbaum FR
    Leukemia; 2001 Feb; 15(2):208-16. PubMed ID: 11236936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.
    Tower RL; Jones TL; Camitta BM; Asselin BL; Bell BA; Chauvenet A; Devidas M; Halperin EC; Pullen J; Shuster JJ; Winick N; Kurtzberg J
    J Pediatr Hematol Oncol; 2014 Jul; 36(5):353-61. PubMed ID: 24608079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
    Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.